In 2012 Birmingham Health Partners leveraged matched funding of £12m from the government as part of the Birmingham City Deal, to establish an ‘Institute of Translational Medicine’ that will serve as the engine to translate laboratory discovery into improved patient care and commercial activity. It will incorporate clinics for a broad range of well-characterised patient cohorts including common and rare diseases, a portal for clinical trials and an early drug discovery unit, clinical bioinformatics and a floor of stratified medicine to include genomics and deep immunophenotyping.
Commercialisation will be maximised through one floor of industry incubator space and there will be an integrated training programme for clinicians, life scientists and allied health professionals to develop the translational researchers of the future. Analytical capacity will be used to deliver increased patient benefit from some of the world’s most complete healthcare data through UHB’s state of the art comprehensive Electronic Medical Records system, recording data from 800,000 adult patients each year.
This allows us to map demographic and complex clinical data from patient cohorts onto phenotyping and genomic information providing a unique opportunity to explore mechanisms of disease and develop personalised medicine through stratification.